Enanta Pharmaceuticals, Inc.ENTANASDAQ

Revenue (LTM)

$65M

-3.4% YoY

Net Income (LTM)

$-82M

+29.4% YoY

Free Cash Flow

$-32M

Revenue CAGR (5Y)

-11.8%

Marginsdeclining

FCF($0.0B)

Unprofitable

Metric	Sep 21	Sep 22	Sep 23	Sep 24	Sep 25
Revenue	97	86↓11.2%	79↓8.1%	68↓14.6%	65↓3.4%
Gross Profit	97	86↓11.2%	79↓8.1%	68↓14.6%	61↓10.2%
Operating Income	-110	-124↓13.0%	-137↓10.8%	-122↑11.3%	-85↑29.9%
Net Income	-79	-122↓54.1%	-134↓9.9%	-116↑13.3%	-82↑29.4%
EBITDA	-104	-119↓14.4%	-123↓3.6%	-105↑15.4%	-71↑32.3%
EPS Diluted	-3.92	-5.91↓50.8%	-6.38↓8.0%	-5.48↑14.1%	-3.84↑29.9%

Metric	Sep 21	Sep 22	Sep 23	Sep 24	Sep 25
Cash & Equivalents	57	44↓23.1%	85↑94.1%	37↓56.4%	32↓13.3%
Total Current Assets	319	312↓2.3%	423↑35.6%	300↓29.1%	204↓31.9%
Total Assets	441	381↓13.7%	462↑21.5%	377↓18.5%	281↓25.5%
Total Current Liabilities	36	30↓17.5%	63↑110.5%	58↓8.4%	49↓15.6%
Total Liabilities	41	59↑43.0%	246↑314.4%	248↑0.9%	216↓12.8%
Total Equity	399	321↓19.6%	217↓32.6%	129↓40.6%	65↓49.8%
Total Debt	7	27↑290.4%	222↑733.5%	226↑1.6%	201↓11.1%
Net Debt	-50	-17↑65.6%	137↑891.8%	189↑37.8%	169↓10.6%

Metric	Sep 21	Sep 22	Sep 23	Sep 24	Sep 25
Operating Cash Flow	-70	-85↓21.1%	-103↓21.7%	-79↑23.6%	-19↑75.5%
Capital Expenditure	-1	-2↓183.3%	-9↓326.3%	-18↓98.1%	-13↑28.1%
Free Cash Flow	-71	-87↓22.8%	-112↓29.1%	-97↑13.8%	-32↑66.7%
Stock-Based Comp	21	27↑28.5%	28↑4.6%	27↓5.0%	19↓30.7%
Net Change in Cash	-30	-10↑67.1%	41↑520.2%	-48↓216.3%	-6↑88.5%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance